Cardiac Imaging to Detect Cardiotoxicity From Proteasome Inhibitors With a View to the ESC Guidelines

In this broadcast entitled 'Cardiac Imaging to Detect Cardiotoxicity From Proteasome Inhibitors in Alignment with ESC Guidelines' the faculty will be addressing the critical balance between therapeutic progress and cardiac safety in oncology. Exploring cutting-edge cardiac imaging techniques, their applications and their integration with ESC's guidelines to ensure patient safety and optimise clinical outcomes.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits. 

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement

This is an independent activity run by the International Cardio-Oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. The IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance, Eli Lilly and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.